Deutsche Bank turns bearish on Novartis as shares recover failed trial losses
In short
Deutsche Bank has revised its outlook on Novartis by adopting a decidedly bearish stance. This strategic adjustment follows a period where the healthcare company's equity rebounded from previous declines. Those earlier losses were originally driven by an unsuccessful clinical trial.
Key points
- Deutsche Bank has adopted a pessimistic outlook following the recent rebound in share val…: Deutsche Bank has adopted a pessimistic outlook following the recent rebound in share value.
- Novartis has successfully erased the equity declines tied to its previous clinical trial…: Novartis has successfully erased the equity declines tied to its previous clinical trial setback.
- The company's recent share price recovery served as the catalyst for the updated analyst…: The company's recent share price recovery served as the catalyst for the updated analyst stance.